8-K Announcements
6Material company update
May 14, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Mar 27, 2026·SEC
RenovoRx, Inc.(RNXT)Earnings, Financials & Key Ratios
RNXT•NASDAQ
Price updated Jun 19, 2026
AboutRenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.Show more
- Revenue$1M+2511.6%
- EBITDA-$13M-14.0%
- Net Income-$11M-26.7%
- EPS (Diluted)-0.32+13.5%
- Gross Margin70.88%-29.1%
- EBITDA Margin-1113.98%+95.6%
- Operating Margin-1113.98%+95.6%
- Net Margin-994.48%+95.1%
- ROE-225.62%+81.1%
RNXT Key Insights
RenovoRx, Inc. (RNXT) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Profits declining 24.1% over 5 years
- ✗Negative free cash flow
- ✗Shares diluted 49.7% in last year
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when RNXT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
RNXT Price & Volume
RenovoRx, Inc. (RNXT) stock price & volume — 10-year historical chart
Loading chart...
RNXT Growth Metrics
RenovoRx, Inc. (RNXT) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM520.42%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-20.78%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM17.26%
Return on Capital
10 Years-223%
5 Years-214.41%
3 Years-297.8%
Last Year-202.72%
RNXT Peer Comparison
RenovoRx, Inc. (RNXT) competitors in Drug Delivery Technology Platforms — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTR | 1.19B | 60.98 | -6.27 | -43.89% | -284.18% | -87% | 1.66 | |
 CRIS | 81.52M | 0.42 | -0.73 | -13.43% | -299.66% | -138.81% | 0.30 | |
 TPVG | 202.99M | 5.00 | 4.10 | 36.55% | -19.55% | -3.39% | 1.33 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 | |||
 CASI | 2.33M | 0.15 | -0.06 | -15.77% | -183.93% | -301.8% | 11.96 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 INVA | 1.66B | 22.49 | 6.82 | 18.52% | 118.91% | 47.59% | 0.23 |
Compare RNXT vs Peers
RenovoRx, Inc. (RNXT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
RNXT Income Statement
RenovoRx, Inc. (RNXT) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 43K | 1.12M | 1.49M |
Revenue Growth % | - | - | - | - | - | - | 2511.63% | 520.42% |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 327K | 317K |
COGS % of Revenue | - | - | - | - | - | - | 29.12% | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 43K▲ 0% | 796K▲ 1751.2% | 1.17M▲ 0% |
Gross Margin % | - | - | - | - | - | 100% | 70.88% | 78.71% |
Gross Profit Growth % | - | - | - | - | - | - | 1751.16% | - |
Operating Expenses | 3.9M | 3.2M | 5.67M | 9.95M | 11.4M | 11.01M | 13.31M | 14.04M |
OpEx % of Revenue | - | - | - | - | - | 25611.63% | 1184.86% | - |
Selling, General & Admin | 899K | 818K | 2.63M | 5.65M | 5.73M | 4.99M | 7.04M | 8.2M |
SG&A % of Revenue | - | - | - | - | - | 11600% | 626.63% | - |
Research & Development | 3M | 2.39M | 3.04M | 4.3M | 5.67M | 6.03M | 6.27M | 5.84M |
R&D % of Revenue | - | - | - | - | - | 14011.63% | 558.24% | - |
Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Operating Income | -3.9M▲ 0% | -3.2M▲ 17.8% | -5.67M▼ 77.0% | -9.95M▼ 75.5% | -11.4M▼ 14.5% | -10.97M▲ 3.7% | -12.51M▼ 14.0% | -12.87M▲ 0% |
Operating Margin % | - | - | - | - | - | -25511.63% | -1113.98% | -864.34% |
Operating Income Growth % | - | 17.76% | -77% | -75.45% | -14.53% | 3.74% | -14.04% | - |
EBITDA | -3.84M | 0 | -5.66M | -9.94M | -11.39M | -10.97M | -12.51M | -12.87M |
EBITDA Margin % | - | - | - | - | - | -25511.63% | -1113.98% | -864.27% |
EBITDA Growth % | - | 100% | - | -75.63% | -14.54% | 3.69% | -14.04% | -43.45% |
D&A (Non-Cash Add-back) | 0 | 3.2M | 9K | 6K | 6K | 0 | 0 | 1K |
EBIT | -3.84M | -3.2M | -5.49M | -9.95M | -11.4M | -10.97M | -12.51M | -12.87M |
Net Interest Income | 63K | -587K | -834K | 0 | -108K | 384K | 427K | 366K |
Interest Income | 63K | 3K | 0 | 57K | 0 | 384K | 427K | 366K |
Interest Expense | 0 | 590K | 834K | 57K | 108K | 0 | 0 | 0 |
Other Income/Expense | 57K | -594K | -653K | 61K | 1.16M | 2.16M | 1.34M | 600K |
Pretax Income | -3.84M▲ 0% | -3.8M▲ 1.1% | -6.32M▼ 66.5% | -9.89M▼ 56.4% | -10.23M▼ 3.5% | -8.81M▲ 13.9% | -11.17M▼ 26.7% | -12.27M▲ 0% |
Pretax Margin % | - | - | - | - | - | -20497.67% | -994.48% | -824.04% |
Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Net Income | -3.84M▲ 0% | -3.8M▲ 1.1% | -6.32M▼ 66.5% | -9.89M▼ 56.4% | -10.23M▼ 3.5% | -8.81M▲ 13.9% | -11.17M▼ 26.7% | -12.27M▲ 0% |
Net Margin % | - | - | - | - | - | -20497.67% | -994.48% | -823.98% |
Net Income Growth % | - | 1.07% | -66.51% | -56.37% | -3.47% | 13.86% | -26.71% | -20.78% |
Net Income (Continuing) | -3.84M | -3.8M | -6.32M | -9.89M | -10.23M | -8.81M | -11.17M | -12.27M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.22▲ 0% | -0.25▼ 13.6% | -0.40▼ 60.0% | -0.54▼ 35.0% | -0.50▲ 7.4% | -0.37▲ 26.0% | -0.32▲ 13.5% | -0.32▲ 0% |
EPS Growth % | - | -13.64% | -60% | -35% | 7.41% | 26% | 13.51% | 17.26% |
EPS (Basic) | -0.22 | -0.25 | -0.40 | -0.54 | -0.50 | -0.37 | -0.32 | - |
Diluted Shares Outstanding | 17.32M | 17.32M | 17.87M | 18.1M | 20.58M | 23.61M | 35.33M | 38.03M |
Basic Shares Outstanding | 17.32M | 17.32M | 17.87M | 18.1M | 20.58M | 23.61M | 35.33M | 38.03M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - |
RNXT Balance Sheet
RenovoRx, Inc. (RNXT) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Total Current Assets | 2.27M | 1.91M | 16.28M | 7.26M | 1.47M | 7.83M | 7.89M | 13.72M |
Cash & Short-Term Investments | 2.1M | 1.79M | 15.19M | 6.44M | 1.17M | 7.15M | 7.02M | 12.36M |
Cash Only | 2.1M | 1.79M | 15.19M | 4.39M | 1.17M | 7.15M | 7.02M | 12.36M |
Short-Term Investments | 0 | 0 | 0 | 2.05M | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 43K | 139K | 280K |
Days Sales Outstanding | - | - | - | - | - | 365 | 45.18 | 58.28 |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 189K | 379K |
Days Inventory Outstanding | - | - | - | - | - | - | 210.96 | 241.8 |
Other Current Assets | 20K | 0 | 0 | 825K | 101K | 303K | 541K | 699K |
Total Non-Current Assets | 4K | 4K | 6K | 0 | 0 | 290K | 202K | 244K |
Property, Plant & Equipment | 0 | 0 | 6K | 0 | 0 | 290K | 202K | 244K |
Fixed Asset Turnover | - | - | - | - | - | 0.15x | 5.56x | 6.47x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 4K | 4K | 0 | 0 | 0 | 0 | 0 | 0 |
Total Assets | 2.27M▲ 0% | 1.91M▼ 15.7% | 16.29M▲ 750.9% | 7.26M▼ 55.4% | 1.47M▼ 79.8% | 8.12M▲ 453.8% | 8.1M▼ 0.3% | 13.96M▲ 0% |
Asset Turnover | - | - | - | - | - | 0.01x | 0.14x | 0.13x |
Asset Growth % | - | -15.68% | 750.94% | -55.39% | -79.82% | 453.75% | -0.28% | 12.28% |
Total Current Liabilities | 805K | 4.1M | 938K | 1.1M | 1.18M | 1.91M | 1.96M | 1.92M |
Accounts Payable | 538K | 162K | 525K | 534K | 561K | 586K | 799K | 1.12M |
Days Payables Outstanding | - | - | - | - | - | - | 891.85 | 995.4 |
Short-Term Debt | 0 | 2.77M | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 35K | 895K | 0 | 475K | 75K | 817K | 1.16M | 801K |
Current Ratio | 2.81x | 0.47x | 17.36x | 6.59x | 1.25x | 4.10x | 4.02x | 7.15x |
Quick Ratio | 2.81x | 0.47x | 17.36x | 6.59x | 1.25x | 4.10x | 3.93x | 6.95x |
Cash Conversion Cycle | - | - | - | - | - | - | -635.71 | -695.32 |
Total Non-Current Liabilities | 0 | 12.47M | 0 | 0 | 3.29M | 1.73M | 711K | 779K |
Long-Term Debt | 0 | 23K | 0 | 0 | 0 | 0 | 107K | 78K |
Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 212K | 0 | 295K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 12.45M | 0 | 0 | 3.29M | 1.52M | 604K | 701K |
Total Liabilities | 805K | 16.57M | 938K | 1.1M | 4.47M | 3.64M | 2.67M | 2.7M |
Total Debt | 0 | 2.79M | 0 | 0 | 0 | 278K | 107K | 78K |
Net Debt | -2.1M | 995K | -15.19M | -4.39M | -1.17M | -6.88M | -6.92M | -12.28M |
Debt / Equity | - | - | - | - | - | 0.06x | 0.02x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | 0.95x |
Interest Coverage | - | -5.43x | -6.58x | -174.56x | -105.52x | - | - | - |
Total Equity | 1.47M▲ 0% | -14.66M▼ 1100.4% | 15.35M▲ 204.7% | 6.16M▼ 59.8% | -3M▼ 148.7% | 4.48M▲ 249.3% | 5.42M▲ 21.1% | 11.27M▲ 0% |
Equity Growth % | - | -1100.41% | 204.73% | -59.85% | -148.68% | 249.27% | 21.08% | 35.71% |
Book Value per Share | 0.08 | -0.85 | 0.86 | 0.34 | -0.15 | 0.19 | 0.15 | 0.30 |
Total Shareholders' Equity | 1.47M | -14.66M | 15.35M | 6.16M | -3M | 4.48M | 5.42M | 11.27M |
Common Stock | 1K | 1K | 1K | 1K | 1K | 2K | 4K | 5K |
Retained Earnings | -11.16M | -14.96M | -21.28M | -31.17M | -41.41M | -50.22M | -61.39M | -64.91M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | -16.29M | 17K | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
RNXT Cash Flow Statement
RenovoRx, Inc. (RNXT) cash flow — operating, investing & free cash flow history
| Metric | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|
Cash from Operations | -3.35M | -3.53M | -5.92M | -8.81M | -10.26M | -9.13M | -10.97M | -11.3M |
Operating CF Margin % | - | - | - | - | - | -21220.93% | -977.11% | - |
Operating CF Growth % | - | -5.31% | -67.69% | -48.94% | -16.42% | 11.04% | -20.25% | -37.66% |
Net Income | -3.84M | -3.8M | -6.32M | -9.89M | -10.23M | -8.81M | -11.17M | -12.27M |
Depreciation & Amortization | 0 | 0 | 9K | 6K | 0 | 0 | 2K | 2K |
Stock-Based Compensation | 38K | 50K | 147K | 644K | 1.08M | 1.17M | 1.27M | 979K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 8K | 489K | 517K | 0 | -1.71M | -1.76M | -827K | 172K |
Working Capital Changes | 443K | -269K | -265K | 428K | 605K | 280K | -247K | -185K |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | -96K | -38K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -189K | -107K |
Change in Payables | 343K | -376K | 363K | 9K | 27K | 25K | 213K | 86K |
Cash from Investing | -1K | 0 | -15K | -2.03M | 2.03M | -12K | -2K | 0 |
Capital Expenditures | 0 | 0 | -15K | 0 | 0 | -12K | -2K | 0 |
CapEx % of Revenue | - | - | - | - | - | 27.91% | 0.18% | 0% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - |
Other Investing | -1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash from Financing | 0 | 3.2M | 19.33M | 42K | 5.01M | 15.12M | 10.85M | 9.08M |
Debt Issued (Net) | 0 | 3.16M | 1.98M | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | 43K | 14.56M | 42K | 5M | 15.02M | 12.14M | 10.35M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | 2.79M | 0 | 8K | 102K | -1.3M | -1.26M |
Net Change in Cash | -3.35M▲ 0% | -329K▲ 90.2% | 13.4M▲ 4172.0% | -10.8M▼ 180.6% | -3.22M▲ 70.2% | 5.98M▲ 285.9% | -130K▼ 102.2% | -2.22M▲ 0% |
Free Cash Flow | -3.35M▲ 0% | -3.53M▼ 5.3% | -5.93M▼ 68.1% | -8.81M▼ 48.6% | -10.26M▼ 16.4% | -9.14M▲ 10.9% | -10.97M▼ 20.1% | -11.3M▲ 0% |
FCF Margin % | - | - | - | - | - | -21248.84% | -977.29% | -758.97% |
FCF Growth % | - | -5.31% | -68.11% | -48.56% | -16.42% | 10.93% | -20.12% | -9.55% |
FCF per Share | -0.19 | -0.20 | -0.33 | -0.49 | -0.50 | -0.39 | -0.31 | -0.30 |
FCF Conversion (FCF/Net Income) | 0.87x | 0.93x | 0.94x | 0.89x | 1.00x | 1.04x | 0.98x | 0.92x |
Interest Paid | 0 | 0 | 0 | 0 | 14K | 21K | 16K | -5K |
Taxes Paid | 0 | 0 | 0 | 0 | 38K | 2K | 1K | 0 |
RNXT Key Ratios
RenovoRx, Inc. (RNXT) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -1825.11% | -91.94% | -646.98% | -1192.69% | -225.62% | -138.61% |
Return on Invested Capital (ROIC) | - | - | -773.72% | - | - | - | 682.52% |
Gross Margin | - | - | - | - | 100% | 70.88% | 78.71% |
Net Margin | - | - | - | - | -20497.67% | -994.48% | -823.98% |
Debt / Equity | - | - | - | - | 0.06x | 0.02x | 0.01x |
Interest Coverage | -5.43x | -6.58x | -174.56x | -105.52x | - | - | - |
FCF Conversion | 0.93x | 0.94x | 0.89x | 1.00x | 1.04x | 0.98x | 0.92x |
Revenue Growth | - | - | - | - | - | 2511.63% | 520.42% |
Related:RNXT Dividend History·RNXT Revenue History·RNXT Price History·RNXT P/E History·RNXT Financial Ratios·RNXT Institutional Holders
RNXT SEC Filings & Documents
RenovoRx, Inc. (RNXT) SEC filings — annual & quarterly reports (10-K, 10-Q)
RNXT Frequently Asked Questions
RenovoRx, Inc. (RNXT) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
RenovoRx, Inc. (RNXT) reported $1.5M in revenue for fiscal year 2025.
RenovoRx, Inc. (RNXT) grew revenue by 2511.6% over the past year. This is strong growth.
RenovoRx, Inc. (RNXT) reported a net loss of $12.3M for fiscal year 2025.
Dividend & Returns
RenovoRx, Inc. (RNXT) has a return on equity (ROE) of -225.6%. Negative ROE indicates the company is unprofitable.
RenovoRx, Inc. (RNXT) had negative free cash flow of $11.3M in fiscal year 2025, likely due to heavy capital investments.